Do analysts rate SBFM or CUPR?

Sunshine Biopharma presently has a consensus target price of $70.00, suggesting a potential upside of 3,653.35%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Sunshine Biopharma is more favorable than Cuprina Holdings (Cayman). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cuprina Holdings (Cayman) 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, SBFM or CUPR?

Cuprina Holdings (Cayman) has lower revenue, but higher earnings than Sunshine Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sunshine Biopharma $35.49M 0.03 -$5.97M -$12.90 N/A Cuprina Holdings (Cayman) $40K 97.29 -$3.63M N/A N/A

Do analysts rate PPCB or SBFM?

Sunshine Biopharma has a consensus target price of $70.00, indicating a potential upside of 3,653.35%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Sunshine Biopharma is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate ALBT or SBFM?

Sunshine Biopharma has a consensus target price of $70.00, indicating a potential upside of 3,653.35%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than Avalon GloboCare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer VCNX or SBFM?

Sunshine Biopharma has a consensus price target of $70.00, indicating a potential upside of 3,653.35%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Sunshine Biopharma is more favorable than Vaccinex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Sunshine Biopharma (SBFM) Competitors

$1.86 +0.01 (+0.27%)

As of 11:31 AM Eastern

Compare

SBFM vs. CUPR, PPCB, GOVX, ALBT, and VCNX

Should you buy Sunshine Biopharma stock or one of its competitors? MarketBeat compares Sunshine Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sunshine Biopharma include Cuprina Holdings (Cayman) (CUPR), Propanc Biopharma (PPCB), GeoVax Labs (GOVX), Avalon GloboCare (ALBT), and Vaccinex (VCNX). These companies are all part of the "pharmaceutical products" industry.

How does Sunshine Biopharma compare to Cuprina Holdings (Cayman)?

Sunshine Biopharma (NASDAQ:SBFM) and Cuprina Holdings (Cayman) (NASDAQ:CUPR) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Cuprina Holdings (Cayman) has lower revenue, but higher earnings than Sunshine Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$35.49M	0.03	-$5.97M	-$12.90	N/A
Cuprina Holdings (Cayman)	$40K	97.29	-$3.63M	N/A	N/A

Cuprina Holdings (Cayman) has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-18.45%	-27.75%	-21.57%
Cuprina Holdings (Cayman)	N/A	N/A	N/A

42.0% of Sunshine Biopharma shares are owned by institutional investors. 0.5% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Sunshine Biopharma presently has a consensus target price of $70.00, suggesting a potential upside of 3,653.35%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Sunshine Biopharma is more favorable than Cuprina Holdings (Cayman).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Sunshine Biopharma and Sunshine Biopharma both had 2 articles in the media. Sunshine Biopharma's average media sentiment score of 1.45 beat Cuprina Holdings (Cayman)'s score of 1.44 indicating that Sunshine Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Sunshine Biopharma	Positive
Cuprina Holdings (Cayman)	Positive

Sunshine Biopharma has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Cuprina Holdings (Cayman) has a beta of -1.1, suggesting that its stock price is 210% less volatile than the broader market.

Summary

Sunshine Biopharma beats Cuprina Holdings (Cayman) on 8 of the 13 factors compared between the two stocks.

How does Sunshine Biopharma compare to Propanc Biopharma?

Propanc Biopharma (NASDAQ:PPCB) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Sunshine Biopharma has a consensus target price of $70.00, indicating a potential upside of 3,653.35%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Sunshine Biopharma is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Propanc Biopharma and Propanc Biopharma both had 2 articles in the media. Sunshine Biopharma's average media sentiment score of 1.45 beat Propanc Biopharma's score of 1.44 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Propanc Biopharma	Positive
Sunshine Biopharma	Positive

Sunshine Biopharma has higher revenue and earnings than Propanc Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
Sunshine Biopharma	$35.49M	0.03	-$5.97M	-$12.90	N/A

Propanc Biopharma has a beta of 3.49, suggesting that its share price is 249% more volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Propanc Biopharma has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Sunshine Biopharma's return on equity of -27.75% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
Sunshine Biopharma	-18.45%	-27.75%	-21.57%

42.0% of Sunshine Biopharma shares are owned by institutional investors. 28.5% of Propanc Biopharma shares are owned by company insiders. Comparatively, 0.5% of Sunshine Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Sunshine Biopharma beats Propanc Biopharma on 10 of the 14 factors compared between the two stocks.

How does Sunshine Biopharma compare to GeoVax Labs?

Sunshine Biopharma (NASDAQ:SBFM) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Sunshine Biopharma has higher revenue and earnings than GeoVax Labs. Sunshine Biopharma is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$35.49M	0.03	-$5.97M	-$12.90	N/A
GeoVax Labs	$852.28K	3.66	-$21.47M	-$19.12	N/A

Sunshine Biopharma presently has a consensus target price of $70.00, indicating a potential upside of 3,653.35%. GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 16,603.79%. Given GeoVax Labs' higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Sunshine Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Sunshine Biopharma has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.68, suggesting that its stock price is 268% more volatile than the broader market.

In the previous week, Sunshine Biopharma and Sunshine Biopharma both had 2 articles in the media. Sunshine Biopharma's average media sentiment score of 1.45 beat GeoVax Labs' score of 1.44 indicating that Sunshine Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Sunshine Biopharma	Positive
GeoVax Labs	Positive

GeoVax Labs has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Sunshine Biopharma's return on equity of -27.75% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-18.45%	-27.75%	-21.57%
GeoVax Labs	N/A	-709.52%	-399.33%

42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 0.5% of Sunshine Biopharma shares are owned by insiders. Comparatively, 0.7% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Sunshine Biopharma beats GeoVax Labs on 9 of the 15 factors compared between the two stocks.

How does Sunshine Biopharma compare to Avalon GloboCare?

Avalon GloboCare (NASDAQ:ALBT) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Sunshine Biopharma has higher revenue and earnings than Avalon GloboCare. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	N/A	N/A	-$18.26M	-$3.51	N/A
Sunshine Biopharma	$35.49M	0.03	-$5.97M	-$12.90	N/A

Avalon GloboCare has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

1.4% of Avalon GloboCare shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 24.2% of Avalon GloboCare shares are held by company insiders. Comparatively, 0.5% of Sunshine Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sunshine Biopharma has a consensus target price of $70.00, indicating a potential upside of 3,653.35%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than Avalon GloboCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Avalon GloboCare had 1 more articles in the media than Sunshine Biopharma. MarketBeat recorded 3 mentions for Avalon GloboCare and 2 mentions for Sunshine Biopharma. Sunshine Biopharma's average media sentiment score of 1.45 beat Avalon GloboCare's score of 0.96 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Avalon GloboCare	Positive
Sunshine Biopharma	Positive

Avalon GloboCare has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Avalon GloboCare's return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-74.36%
Sunshine Biopharma	-18.45%	-27.75%	-21.57%

Summary

Sunshine Biopharma beats Avalon GloboCare on 9 of the 15 factors compared between the two stocks.

How does Sunshine Biopharma compare to Vaccinex?

Vaccinex (NASDAQ:VCNX) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Sunshine Biopharma has higher revenue and earnings than Vaccinex. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	7.77	-$20.25M	-$48.27	N/A
Sunshine Biopharma	$35.49M	0.03	-$5.97M	-$12.90	N/A

Sunshine Biopharma has a consensus price target of $70.00, indicating a potential upside of 3,653.35%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Sunshine Biopharma is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Sunshine Biopharma had 2 more articles in the media than Vaccinex. MarketBeat recorded 2 mentions for Sunshine Biopharma and 0 mentions for Vaccinex. Sunshine Biopharma's average media sentiment score of 1.45 beat Vaccinex's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Vaccinex	Neutral
Sunshine Biopharma	Positive

Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Vaccinex has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Vaccinex's return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Sunshine Biopharma	-18.45%	-27.75%	-21.57%

50.1% of Vaccinex shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 51.5% of Vaccinex shares are held by company insiders. Comparatively, 0.5% of Sunshine Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Sunshine Biopharma beats Vaccinex on 10 of the 16 factors compared between the two stocks.

Get Sunshine Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SBFM vs. The Competition

Export

Metric	Sunshine Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$934K	$3.70B	$6.88B	$12.57B
Dividend Yield	N/A	2.22%	2.68%	9.45%
P/E Ratio	-0.14	21.47	27.24	24.31
Price / Sales	0.03	167.91	509.95	88.89
Price / Cash	N/A	143.89	48.63	60.00
Price / Book	0.04	8.54	10.95	6.28
Net Income	-$5.97M	$23.88M	$3.59B	$331.55M
7 Day Performance	-12.85%	-4.19%	-1.90%	-1.36%
1 Month Performance	-12.85%	6.40%	3.54%	-0.43%
1 Year Performance	-87.73%	47.54%	26.74%	19.22%

Sunshine Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SBFM Sunshine Biopharma	3.1902 of 5 stars	$1.87 +0.3%	$70.00 +3,653.4%	-87.7%	$934K	$35.49M	N/A	3	Positive News Short Interest Decrease
CUPR Cuprina Holdings (Cayman)	0.9104 of 5 stars	$4.12 +0.8%	N/A	N/A	$3.79M	$40K	N/A	14	Positive News Gap Down
PPCB Propanc Biopharma	1.0728 of 5 stars	$1.62 -0.9%	N/A	-98.7%	$3.68M	N/A	N/A	1
GOVX GeoVax Labs	2.9353 of 5 stars	$1.03 -2.3%	$150.00 +14,519.9%	-94.1%	$3.59M	$2.49M	N/A	10	Positive News
ALBT Avalon GloboCare	0.8325 of 5 stars	$0.28 +10.1%	N/A	-89.5%	$3.42M	$1.26M	N/A	5	News Coverage Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SBFM) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sunshine Biopharma (SBFM) Competitors

SBFM vs. CUPR, PPCB, GOVX, ALBT, and VCNX

How does Sunshine Biopharma compare to Cuprina Holdings (Cayman)?

Summary

How does Sunshine Biopharma compare to Propanc Biopharma?

Summary

How does Sunshine Biopharma compare to GeoVax Labs?

Summary

How does Sunshine Biopharma compare to Avalon GloboCare?

Summary

How does Sunshine Biopharma compare to Vaccinex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM vs. The Competition

Sunshine Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sunshine Biopharma (SBFM) Competitors

SBFM vs. CUPR, PPCB, GOVX, ALBT, and VCNX

How does Sunshine Biopharma compare to Cuprina Holdings (Cayman)?

Which has higher valuation & earnings, SBFM or CUPR?

Is SBFM or CUPR more profitable?

Do institutionals & insiders hold more shares of SBFM or CUPR?

Do analysts rate SBFM or CUPR?

Does the media prefer SBFM or CUPR?

Which has more volatility and risk, SBFM or CUPR?

Summary

How does Sunshine Biopharma compare to Propanc Biopharma?

Do analysts rate PPCB or SBFM?

Does the media refer more to PPCB or SBFM?

Which has better earnings & valuation, PPCB or SBFM?

Which has more risk & volatility, PPCB or SBFM?

Is PPCB or SBFM more profitable?

Do institutionals & insiders have more ownership in PPCB or SBFM?

Summary

How does Sunshine Biopharma compare to GeoVax Labs?

Which has preferable valuation and earnings, SBFM or GOVX?

Do analysts prefer SBFM or GOVX?

Which has more risk & volatility, SBFM or GOVX?

Does the media prefer SBFM or GOVX?

Is SBFM or GOVX more profitable?

Do institutionals and insiders have more ownership in SBFM or GOVX?

Summary

How does Sunshine Biopharma compare to Avalon GloboCare?

Which has preferable earnings & valuation, ALBT or SBFM?

Which has more volatility and risk, ALBT or SBFM?

Do insiders and institutionals believe in ALBT or SBFM?

Do analysts rate ALBT or SBFM?

Does the media prefer ALBT or SBFM?

Is ALBT or SBFM more profitable?

Summary

How does Sunshine Biopharma compare to Vaccinex?

Which has stronger earnings & valuation, VCNX or SBFM?

Do analysts prefer VCNX or SBFM?

Does the media prefer VCNX or SBFM?

Which has more risk & volatility, VCNX or SBFM?

Is VCNX or SBFM more profitable?

Do institutionals and insiders believe in VCNX or SBFM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM vs. The Competition

Sunshine Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools